




DERMAGNOSTIX

moving diagnostic frontiers in dermatology

In dermatology, diagnostic methods have not kept pace with therapeutic advances



With its first molecular test „PsorX“ Dermagnostix closes a huge diagnostic gap

Therapeutics for psoriasis and eczema

10-50% of patients with psoriasis and eczema are misdiagnosed.^{9,10}



Imprecise diagnostics make modern therapeutics ineffective and even harmful.¹¹

Diagnostics for psoriasis and eczema


Therapeutics for psoriasis and eczema



PsorX – the first accurate molecular test worldwide for inflammatory skin diseases

Diagnostics for psoriasis and eczema

PsorX – from science to product



PsorX is a breakthrough for modern diagnostics of inflammatory skin diseases


12. Eyerich S, Onken AT, Weidinger S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011;365:231-8. 13. Quaranta M, Knapp B, Garzorz N, et al. Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Science translational medicine 2014;6:244ra90. 14. Garzorz-Stark N, Krause L, Lauffer F, et al. A novel molecular disease classifier for psoriasis and eczema. Experimental dermatology 2016;25:767-74.

PsorX- the first gene expression-based assay performed in a fully automated miniature laboratory

PsorX-LabDisk & LabDisk-Analyzer

PsorX-LabDisk (CE-IVD)

FFPE sample*



Sample in

PsorX-LabDisk 2.0 (under development)

Non-invasive tape strip



Sample in



Answer out



1

Load LabDisk with sample

2

Insert LabDisk into LabDisk-Analyzer

3

Fully automated analysis

4

Accurate result** within 2h

1 assay patent, 12 microfluidics patents, 1 biomarker patent

* = FFPE (Formalin-fixed paraffin-embedded tissue) block, histological tissue sample


**Probability of a sample to be assigned to the molecular signature of psoriasis versus eczema

Full proprietary pipeline of diagnostic tests for unmet clinical needs



PsorX in 2022

Differential diagnosis of psoriasis and eczema
Early reimbursement by DGUV*, first use in industrial trial
with Leo Pharma – unrivalled



OncogeneX in 2024

Therapy relevant tumor mutations and prognostic signature
(melanoma, colon carcinoma, lung cancer)
fully reimbursed – unrivalled



PredX in 2025

Prediction of treatment response to biologicals
10x cost reduction in biological therapy – unrivalled

*DGUV: German Social Accident Insurance – 64.2 M insured individuals



Contact:

Natalie Garzorz-Stark, MD, PhD, MHBA, CEO
n.garzorz-stark@dermagnostix.com